Atara Biotherapeutics financials
$8.05−3.82%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Quarter | Q2 '26 Jun 30 | Q1 '26 Mar 31 | Q4 '25 Dec 31 | Q3 '25 Sep 30 | Q2 '25 Jun 30 | Q1 '25 Mar 31 | Q4 '24 Dec 31 | Q3 '24 Sep 30 | Q2 '24 Jun 30 | Q1 '24 Mar 31 | Q4 '23 Dec 31 | Q3 '23 Sep 30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $630.0K | $516.0K | $1.6M | $3.5M | $17.6M | $98.1M | $32.8M | $40.2M | $28.6M | $27.4M | $4.3M | $2.1M |
| Gross profit | $439.0K | $392.0K | $1.5M | $3.3M | $17.0M | $77.7M | $26.0M | $32.6M | $24.0M | $25.4M | $10.0M | -$477.0K |
| Gross margin | 69.7% | 76.0% | 93.5% | 96.7% | 96.8% | 79.2% | 79.3% | 81.1% | 83.8% | 92.7% | 234.7% | −22.3% |
| Operating income | -$4.7M | -$3.4M | -$2.6M | -$3.6M | $3.2M | $38.8M | -$12.2M | -$21.8M | -$18.2M | -$31.2M | -$60.0M | -$69.6M |
| Net income | -$4.8M | -$4.1M | -$3.4M | -$4.3M | $2.4M | $38.0M | -$12.7M | -$21.9M | -$19.0M | -$31.8M | -$60.5M | -$69.8M |
| Net margin | −767.3% | −803.3% | −213.5% | −124.6% | 13.6% | 38.7% | −38.8% | −54.5% | −66.5% | −116.1% | −1421.7% | −3264.6% |
| Diluted EPS | $-0.32 | $-0.29 | $-0.24 | $-0.32 | $0.19 | $3.50 | $-1.18 | $-2.93 | $-3.10 | $-5.65 | $-4.86 | $-16.40 |
| EBITDA | -$4.7M | -$3.3M | -$2.5M | -$3.5M | $3.4M | $40.6M | -$11.1M | -$20.5M | -$16.9M | -$29.9M | -$58.8M | -$68.4M |
| Operating cash flow | -$3.3M | -$3.1M | -$5.7M | -$9.8M | -$7.3M | -$28.1M | -$24.5M | -$4.0M | -$10.6M | -$29.6M | -$50.4M | -$51.3M |
| Free cash flow | -$3.3M | -$3.1M | -$5.7M | -$9.8M | -$7.3M | -$28.1M | -$24.6M | -$4.0M | -$10.7M | -$29.7M | -$50.5M | -$51.6M |
| Diluted shares | 15.0M | 14.1M | 14.1M | 13.6M | 12.3M | 10.9M | 10.7M | 7.5M | 6.1M | 5.6M | 12.4M | 4.3M |
Balance sheet
| Period end | Jun 30 | Mar 31 | Dec 31 | Sep 30 | Jun 30 | Mar 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $3.2M | $8.4M | $8.5M | $5.7M | $16.9M | $13.8M |
| Short-term investments | $6.7M | $0.00 | $0.00 | $8.0M | $5.4M | $0.00 |
| Total debt | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total assets | $21.0M | $20.0M | $20.2M | $30.2M | $36.9M | $62.0M |
| Total liabilities | $58.0M | $57.3M | $58.7M | $66.8M | $71.9M | $117.1M |
| Shareholders' equity | -$37.0M | -$37.3M | -$38.5M | -$36.6M | -$35.0M | -$55.1M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology